Aimed Bio
| Market cap | ₩1.7T |
| PE ratio | 41.44 |
| Forward PE | – |
| PB ratio | 8.19 |
| EPS | ₩625 |
| Dividend (yield) | – |
| Analysts (1–5) | – |
| Price target | – |
| Volume | 98,115 |
| Trading value | ₩2.5B |
| Day’s range | ₩25,550 – ₩26,450 |
| 52-week range | ₩17,400 – ₩80,200 |
| Foreign ownership KR | 3.05% |
| Foreign net buy (Oct 6) KR | −14,350 sh |
| Book value / share | ₩3,161 |
| Founded | 2018 |
Close (KRW) Foreign ownership, % of shares (right axis)
Foreign, institutional and retail net buying KR data
Shares by trading day; positive means net buying. Korea publishes investor-type flows for every stock — global sites such as Yahoo or StockAnalysis do not show them.
| Date | Close | Foreigners | Institutions | Retail | Foreign ownership |
|---|---|---|---|---|---|
| Oct 6 | ₩25,800 | −14,350 | +7,123 | +7,205 | 3.05% |
| Oct 2 | ₩24,800 | −14,789 | −1,063 | +15,155 | 3.11% |
| Oct 1 | ₩25,450 | +52,780 | +38,546 | −93,917 | 3.16% |
| Sep 30 | ₩22,350 | +40,173 | −3,337 | −36,841 | 2.98% |
| Sep 29 | ₩21,500 | −15,629 | −16,731 | +31,548 | 2.90% |
Financials
Annual, consolidated where available, KRW. Columns ending in E are analyst consensus estimates. Source: company filings (DART) via Naver Finance.
| Item | FY2023 | FY2024 | FY2025 | FY2026E |
|---|---|---|---|---|
| Revenue | ₩200.0M | ₩11.8B | ₩47.3B | – |
| Operating income | −₩6.4B | −₩400.0M | ₩20.8B | – |
| Net income | −₩9.0B | −₩3.3B | ₩5.0B | – |
| Operating margin | −3,747.54% | −3.47% | 43.93% | – |
| Return on equity | −111.82% | −65.72% | 5.13% | – |
| Debt-to-equity | 234.31% | 1,299.77% | 3.32% | – |
| EPS | −₩257 | −₩73 | ₩92 | – |
| Dividend per share | – | – | – | – |
Peers
| Alteogen 196170 | ₩257,000 | −1.15% |
| ABL Bio 298380 | ₩51,100 | −2.67% |
| Hugel 145020 | ₩183,600 | +1.16% |
| Peptron 087010 | ₩130,600 | 0.00% |
| D&D Pharmatech 347850 | ₩46,100 | −3.05% |
| Naturecell 007390 | ₩24,700 | −0.20% |
About
Aimed Bio, founded in 2018 as a hospital spin-off, is a biotech developing antibody-drug conjugate (ADC) cancer drugs and is listed on the KOSDAQ as a technology growth company. It discovers antibodies using patient-derived models and has its own linker-payload technology covering the full ADC development cycle. It has licensed out AMB302 and signed agreements with partners including Boehringer Ingelheim.
Aimed Bio Inc. is listed on the KOSDAQ market of the Korea Exchange under the ticker 0009K0. Industry: Research & development.
Aimed Bio in our notes
Direct KRX access through a global broker, a US-listed ADR where one exists, or a Korea ETF — compared in our guide.
Data: Korea Exchange regular-session closing prices, volume and day’s range via Daum Finance, checked against a Naver Finance snapshot at the close; investor flows, foreign ownership and ratios via Naver Finance; company information from DART (Financial Supervisory Service). Updated after each Korean market close; ratios as of Oct 7, 2026; investor flows as of Oct 6, 2026. Delayed data, not investment advice.